GLP-1 Analogs Research: Semaglutide and Liraglutide Analytics

Structural Engineering for Extended Pharmacokinetics

The transition to long-acting efficacy was achieved through strategic amino acid substitutions and lipidization:

Liraglutide: By substituting Lysine at position 34 with Arginine and attaching a C16 fatty acid (palmitic acid) via a glutamic acid spacer at Lys26, Liraglutide facilitates non-covalent binding to serum albumin. This steric hindrance shields the peptide from proteolytic cleavage and reduces renal clearance.

Semaglutide: Building upon the Liraglutide blueprint, Semaglutide incorporates a synthetic amino acid (Aib at position 8) to specifically obstruct DPP-4. Furthermore, the attachment of a C18 fatty diacid chain via a specialized hydrophilic spacer significantly enhances its affinity for albumin, extending its clinical half-life to approximately 165 hours, supporting once-weekly dosing.

Surveillance of Structural Integrity

The structural state of GLP-1 analogs is an equally critical, yet often overlooked. Human GLP-1 and analogues thereof are known to be prone to form various types of aggregates in solution. A type of such aggregates, fibrils, may reduced pharmacological potency and therefore should be kept at a minimum in drug products for administration to patients in liquid form. Currently, fibril detection is commonly performed using Thioflavin T (ThT), a fluorophore whose emission spectrum changes upon binding to fibrillar structures. However, ThT-based assays often require prior sample stressing to amplify fibril formation to detectable levels. This additional stressing step is time-consuming and undesirable, as it may alter the native state of the sample. Therefore, more sensitive methods are needed to detect peptide fibrils directly, including in complex mixtures where fibrillar species coexist with soluble peptide forms.

Creative Diagnostics offers high quality Anti-Semaglutide and Liraglutide antibodies for quantitative analysis, alongside Anti-Liraglutide fibrils antibodies for monitoring peptide aggregation. The following validation data illustrates the performance of these antibodies across various experimental platforms, providing a baseline for their integration into your metabolic study workflows.